Literature DB >> 21732158

Macrophage-specific targeting of isoniazid through mannosylated gelatin microspheres.

Sanjay Tiwari1, Adya P Chaturvedi, Yamini B Tripathi, Brahmeshwar Mishra.   

Abstract

Active targeting of drug molecules can be achieved by effective attachment of suitable ligands to the surface of carriers. The present work was attempted to prepare mannosylated gelatin microspheres (m-GMs) so as to achieve targeted delivery of isoniazid (INH) to alveolar macrophages (AMs) and maintain its therapeutic concentration for prolonged period of time. Microspheres were prepared by emulsification solvent extraction method and evaluated for physicochemical characteristics, drug release, ex vivo drug uptake by AMs and pharmacokinetic characteristics. Fourier transform infrared spectroscopy and nuclear magnetic resonance spectral analysis confirmed that mannosylation took place through Schiff base formation between aldehyde and amino groups of mannose and gelatin, respectively. Prepared microspheres offered suitable physicochemical characteristics for their delivery to AMs. Their average size was about 4 μm and drug entrapment efficiency of 56% was achieved with them. Ex vivo uptake results indicated that in comparison to plain microspheres, m-GMs were selectively uptaken and were found to be associated with phago-lysosomal vesicles of AMs. Pharmacokinetic studies showed the formulation could maintain the therapeutic concentration of INH for prolonged period of time even with a reduced clinical dose. m-GMs were found to be stable in broncheo-alveolar lavage fluid. The study concluded that ligand decorated carriers could be a potential strategy to improve the therapeutic properties of INH.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21732158      PMCID: PMC3167252          DOI: 10.1208/s12249-011-9654-6

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  29 in total

1.  Egg shell membrane as a substrate for optimizing in vitro transbuccal delivery of glipizide.

Authors:  Anil K Philip; Nisha Singh; Kamla Pathak
Journal:  Pharm Dev Technol       Date:  2009       Impact factor: 3.133

2.  Physicochemical behavior and cytotoxic effects of p(methacrylic acid-g-ethylene glycol) nanospheres for oral delivery of proteins.

Authors:  Madeline Torres-Lugo; Marcos García; Rae Record; Nicholas A Peppas
Journal:  J Control Release       Date:  2002-04-23       Impact factor: 9.776

3.  Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis.

Authors:  Ramesh Jayaram; Radha K Shandil; Sheshagiri Gaonkar; Parvinder Kaur; B L Suresh; B N Mahesh; R Jayashree; Vrinda Nandi; Sowmya Bharath; E Kantharaj; V Balasubramanian
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

4.  Neoglycosylated liposomes as efficient ligands for the evaluation of specific sugar receptors on macrophages in health and in experimental leishmaniasis.

Authors:  M Dutta; R Bandyopadhyay; M K Basu
Journal:  Parasitology       Date:  1994-08       Impact factor: 3.234

5.  Ligand directed macrophage targeting of amphotericin B loaded liposomes.

Authors:  S P Vyas; Y K Katare; V Mishra; V Sihorkar
Journal:  Int J Pharm       Date:  2000-12-04       Impact factor: 5.875

6.  Synthesis, degradation, and antimicrobial properties of targeted macromolecular prodrugs of norfloxacin.

Authors:  Eveline Roseeuw; Veerle Coessens; Anne-Marie Balazuc; Micheline Lagranderie; Pierre Chavarot; Augusto Pessina; Maria Grazia Neri; Etienne Schacht; Gilles Marchal; Dominique Domurado
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

Review 7.  Clinical pharmacokinetics of isoniazid.

Authors:  W W Weber; D W Hein
Journal:  Clin Pharmacokinet       Date:  1979 Nov-Dec       Impact factor: 6.447

8.  Oligonucleotide targeting to alveolar macrophages by mannose receptor-mediated endocytosis.

Authors:  W W Liang; X Shi; D Deshpande; C J Malanga; Y Rojanasakul
Journal:  Biochim Biophys Acta       Date:  1996-03-13

Review 9.  Clinical pharmacokinetics of the antituberculosis drugs.

Authors:  M R Holdiness
Journal:  Clin Pharmacokinet       Date:  1984 Nov-Dec       Impact factor: 6.447

10.  The macrophage capacity for phagocytosis.

Authors:  G J Cannon; J A Swanson
Journal:  J Cell Sci       Date:  1992-04       Impact factor: 5.285

View more
  6 in total

1.  Recent Developments in Drug Delivery for Treatment of Tuberculosis by Targeting Macrophages.

Authors:  Anirudh Gairola; Aaron Benjamin; Joshua D Weatherston; Jeffrey D Cirillo; Hung-Jen Wu
Journal:  Adv Ther (Weinh)       Date:  2022-03-09

Review 2.  Current Development of Nano-Drug Delivery to Target Macrophages.

Authors:  Donglin Cai; Wendong Gao; Zhelun Li; Yufeng Zhang; Lan Xiao; Yin Xiao
Journal:  Biomedicines       Date:  2022-05-23

3.  Newly synthesized surfactants for surface mannosylation of respirable SLN assemblies to target macrophages in tuberculosis therapy.

Authors:  Eleonora Maretti; Luca Costantino; Francesca Buttini; Cecilia Rustichelli; Eliana Leo; Eleonora Truzzi; Valentina Iannuccelli
Journal:  Drug Deliv Transl Res       Date:  2019-02       Impact factor: 4.617

4.  Specifically targeted delivery of protein to phagocytic macrophages.

Authors:  Min Yu; Zeming Chen; Wenjun Guo; Jin Wang; Yupeng Feng; Xiuqi Kong; Zhangyong Hong
Journal:  Int J Nanomedicine       Date:  2015-03-04

5.  Preparation and characterization of beta-glucan particles containing a payload of nanoembedded rifabutin for enhanced targeted delivery to macrophages.

Authors:  Tarun K Upadhyay; Nida Fatima; Deepak Sharma; V Saravanakumar; Rolee Sharma
Journal:  EXCLI J       Date:  2017-03-07       Impact factor: 4.068

6.  Synthesis and Characterization of pH-Sensitive Inulin Conjugate of Isoniazid for Monocyte-Targeted Delivery.

Authors:  Franklin Afinjuomo; Thomas G Barclay; Ankit Parikh; Rosa Chung; Yunmei Song; Gayathri Nagalingam; Jamie Triccas; Lixin Wang; Liang Liu; John D Hayball; Nikolai Petrovsky; Sanjay Garg
Journal:  Pharmaceutics       Date:  2019-10-28       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.